Key Highlights
- Virax Biolabs secured an exclusive distribution agreement with Fosun Diagnostics spanning six countries in Southeast Asia
- The partnership focuses on the ImmuneSelect immune profiling portfolio designed for research applications
- Tuberculosis research in Thailand will serve as the initial market entry point before regional expansion
- Fosun Diagnostics operates under Fosun Pharma, a company with approximately $5.8 billion in 2025 revenues
- Shares of VRAX jumped more than 241% following the announcement; the company maintains a market capitalization of $2.53M
On July 9, 2026, Virax Biolabs (VRAX) revealed that its United Kingdom-based subsidiary had finalized an exclusive regional distribution partnership with Fosun Diagnostics. The announcement triggered a dramatic 241% surge in VRAX shares during trading.
Virax Biolabs Group Limited, VRAX
The partnership grants Fosun Diagnostics exclusive rights to distribute Virax’s ImmuneSelect product portfolio—a collection of research-only immune profiling tools—throughout six key Southeast Asian nations: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia.
Fosun Diagnostics functions as part of Fosun Medtech, which operates within the larger Fosun Pharma organization. With Fosun Pharma reporting 2025 revenues reaching RMB 41.662 billion (approximately $5.8 billion), Virax has secured a financially robust distribution channel across the region.
According to the agreement’s structure, Virax will deliver products such as ELISpot assay plates—laboratory tools designed to assess cellular immune responses—to Fosun through standard purchase order processes. The pricing model incorporates volume-dependent discount tiers.
The partnership becomes operational immediately, with initial focus concentrated on tuberculosis research applications within Thailand before gradually extending to the remaining five markets.
The exclusivity provisions remain contingent upon meeting specified minimum purchase volumes and performance benchmarks. Should these targets go unmet, the exclusive nature of the arrangement may be subject to reconsideration.
The agreement’s structure also provides flexibility for future expansion into additional product categories, increased supply volumes, and possible OEM or private-label manufacturing opportunities.
Understanding ImmuneSelect
ImmuneSelect represents Virax’s commercially launched research-only product suite. This line operates independently from ViraxImmune, the company’s diagnostic platform currently undergoing clinical trials and regulatory review processes.
This differentiation is significant. While ImmuneSelect has already entered commercial distribution and is attracting buyer interest, ViraxImmune remains in the developmental pipeline.
James Foster, serving as Chairman and CEO of Virax Biolabs, described the partnership as “a major step forward in the commercial rollout” of the ImmuneSelect system throughout Southeast Asia.
Leon Zhang, who leads International Commercial operations for China Domestic Business at Fosun MedTech, indicated that Fosun is currently assessing ELISpot-based research opportunities across the regional market.
Background on VRAX
Virax Biolabs operates with a market capitalization of merely $2.53 million, categorizing it as a micro-cap equity. The stock’s average daily trading volume hovers around 1.05 million shares.
The latest analyst coverage on VRAX issued a Buy recommendation, establishing a price target of $1.00.
Technical analysis indicators currently flash a Sell signal for the stock, creating an interesting contrast with today’s explosive upward price movement.
The 241% intraday spike has thrust the stock into the spotlight, though price volatility of this magnitude is relatively common for companies with such small market capitalizations when significant news breaks.
As of July 9, 2026, the supply arrangement is fully active, enabling Fosun to submit purchase orders immediately under the terms of the agreement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
